Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?
Küçük Resim Yok
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Zerbinis Publications
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Purpose: To demonstrate whether early changes in systemic inflammatory markers are related with pazopanib treatment response in soft tissue sarcoma and renal cell carcinoma. Methods: Forty-one patients with metastatic clear cell renal carcinoma (mRCC) (n=22) and advanced stage soft tissue sarcoma (STS) (n=19) were assessed. Systemic inflammatory markers such as neutrophils, lymphocytes, c-reactive protein (CRP), mean platelet volume (MPV), lactate dehydrogenase (LDH) and neutrophil-lymphocyte ratio (NLR) and platelet-lymphocyte ratio (PLR) at both baseline and 1-month of pazopanib treatment were obtained and their relation with the first radiological response about 3-months later after pazopanib treatment was evaluated. Results: Disease control rate (DCR) at the first initial radiological evaluation was 58.5 % for all, it was 77.3% for the RCC group and 36.8% in the STS group. Serum neutrophil, NLR and CRP levels were significantly decreased from baseline in RCC patients who had DCR with pazopanib treatment. Also, serum CRP levels after pazopanib treatment was significantly lower in RCC patients who had DCR (+) rather than those who progressed. Conclusions: Early decline in serum CRP, neutrophil and NLR levels in RCC patients who received pazopanib at the first month was significantly associated with disease control, assuming a predictive role for the first radiological assessment. However, there was no significant association between change in serum inflammatory marker levels and disease control in STS patients. © 2021 Zerbinis Publications. All rights reserved.
Açıklama
Anahtar Kelimeler
Disease Control; Inflammatory Markers; Metastatic Renal Cell Carcinoma; Pazopanib; Soft Tissue Sarcoma, Biological Marker; C Reactive Protein; Interferon; Lactate Dehydrogenase; Pazopanib; Biological Marker; Indazole Derivative; Pazopanib; Pyrimidine Derivative; Sulfonamide; Adult; Aged; Cancer Control; Cancer Patient; Cancer Staging; Clear Cell Renal Cell Carcinoma; Clinical Article; Clinical Assessment; Comparative Effectiveness; Controlled Study; Drug Efficacy; Female; Human; Inflammation; Kidney Metastasis; Lymphocyte Count; Male; Mean Platelet Volume; Neutrophil Count; Neutrophil Lymphocyte Ratio; Platelet Lymphocyte Ratio; Radiography; Renal Cell Carcinoma; Retrospective Study; Review; Soft Tissue Sarcoma; Treatment Outcome; Treatment Response; Blood; Complication; Inflammation; Kidney Tumor; Middle Aged; Pathology; Sarcoma; Soft Tissue Tumor; Time Factor; Aged; Biomarkers; Carcinoma, Renal Cell; Female; Humans; Indazoles; Inflammation; Kidney Neoplasms; Male; Middle Aged; Neoplasm Staging; Pyrimidines; Retrospective Studies; Sarcoma; Soft Tissue Neoplasms; Sulfonamides; Time Factors; Treatment Outcome
Kaynak
Journal of B.U.ON.
WoS Q Değeri
Scopus Q Değeri
Q3
Cilt
26
Sayı
5
